MSON - Misonix, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
21.72
-0.88 (-3.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close22.60
Open22.53
Bid21.27 x 900
Ask22.50 x 800
Day's Range21.72 - 22.90
52 Week Range13.19 - 27.54
Volume52,062
Avg. Volume68,179
Market Cap209.405M
Beta (3Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-0.75
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Misonix to Present at the 39th Annual Canaccord Genuity Growth Conference on August 8

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the Canaccord Genuity 39th Annual Growth Conference held at the InterContinental Hotel in Boston, Massachusetts on Thursday, August 8, 2019. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, will be making a company presentation in the Vancouver Room at 11:00 a.m. ET that day. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • Benzinga20 days ago

    The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arena Pharmaceuticals, ...

  • GlobeNewswire21 days ago

    Misonix Announces Inclusion in the Russell 2000® and 3000 Indexes

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has been selected to be added to the broad-market Russell 2000 and 3000® Indexes as part of the annual reconstitution of the Russell stock indexes. The Russell index changes became effective at the market close on June 28, 2019.  Misonix is already included in the Russell MicroCap Index. “We are very pleased to be added to the Russell 2000 and 3000 Indexes,” stated Stavros Vizirgianakis, President and Chief Executive Officer of Misonix.

  • GlobeNewswirelast month

    SEC Investigation of Misonix, Inc. Ends With No Action

    Misonix, Inc. (MSON) (“Misonix”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it has received a letter from the Division of Enforcement of the Securities and Exchange Commission (the “SEC”) on June 18, 2019, stating that the SEC has concluded its investigation of Misonix and that, based on the information it has as of the date of the letter, it does not intend to recommend an enforcement action by the SEC against Misonix with respect to the matters described below. As previously disclosed, with the assistance of outside counsel, Misonix conducted a voluntary investigation into the business practices of the independent Chinese entity that previously distributed Misonix’s products in China and Misonix’s knowledge of those business practices, which may have had implications under the U.S. Foreign Corrupt Practices Act, as well as into various internal controls issues identified during the investigation.

  • The Misonix (NASDAQ:MSON) Share Price Is Up 363% And Shareholders Are Delighted
    Simply Wall St.last month

    The Misonix (NASDAQ:MSON) Share Price Is Up 363% And Shareholders Are Delighted

    Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Mistakes are...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of MSON earnings conference call or presentation 8-May-19 8:30pm GMT

    Q3 2019 Misonix Inc Earnings Call

  • GlobeNewswire2 months ago

    Misonix Receives U.S. FDA Clearance for Nexus, its Revolutionary Integrated Ultrasonic Surgical Platform

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for Nexus, its revolutionary ultrasonic surgical platform. Misonix will commence the commercialization of the Nexus platform in the United States in July. Nexus is a next-generation integrated ultrasonic surgical platform that combines all the features of Misonix’s existing solutions, including BoneScalpel, SonicOne and Sonastar, into a single fully integrated platform that will also serve to power future solutions.

  • GlobeNewswire2 months ago

    Misonix to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor Conference held at the Depot Renaissance Minneapolis Hotel in Minneapolis, Minnesota on Wednesday, May 29, 2019. Misonix management will be available to meet with institutional investors in one-on-one meetings throughout the day at the conference. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • Associated Press2 months ago

    Misonix: Fiscal 3Q Earnings Snapshot

    On a per-share basis, the Farmingdale, New York-based company said it had a loss of 17 cents. The maker of minimally invasive ultrasonic surgical devices for spine surgery posted revenue of $9.6 million ...

  • GlobeNewswire2 months ago

    Misonix Reports Fiscal 2019 Third Quarter Revenue of $9.6 Million

    FARMINGDALE, N.Y., May 08, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • Benzinga3 months ago

    Misonix Announces $97M Acquisition Of Solys Medical

    Medical device maker  Misonix, Inc. (NASDAQ: MSON ) announced Thursday that it entered a definitive agreement to acquire privately held  Solsys Medical, LLC  in an all-stock transaction valued at about $97 ...

  • GlobeNewswire3 months ago

    Misonix, Inc. Enters Into Definitive Agreement to Acquire Regenerative Medical Company Solsys Medical for Approximately $97 Million

    FARMINGDALE, N.Y., May 02, 2019 (GLOBE NEWSWIRE) --  Misonix, Inc. (MSON) (“Misonix”) a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today that it has entered into a definitive agreement with Solsys Medical, LLC (“Solsys”), a privately held regenerative medical company, to acquire Solsys in an all-stock transaction valued at approximately $97 million. Under the terms of the agreement, Misonix will issue approximately 5.7 million new shares to Solsys unitholders.

  • Loss-Making Misonix, Inc. (NASDAQ:MSON) Expected To Breakeven
    Simply Wall St.3 months ago

    Loss-Making Misonix, Inc. (NASDAQ:MSON) Expected To Breakeven

    Misonix, Inc.'s (NASDAQ:MSON): Misonix, Inc., together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacifi...

  • GlobeNewswire3 months ago

    Misonix to Report Fiscal 2019 Third Quarter Financial Results and Host Conference Call and Webcast on May 8

    FARMINGDALE, N.Y., April 10, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire5 months ago

    Misonix To Present At The 9th Annual Canaccord Genuity Musculoskeletal Conference On March 12

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 9th Annual Canaccord Genuity Musculoskeletal Conference held at the Bally's Las Vegas Hotel in Las Vegas, Nevada on Tuesday, March 12, 2019. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, is scheduled to present at 11:30 a.m. PT / 2:30 p.m. ET that day. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • GlobeNewswire5 months ago

    Misonix Names Sharon Klugewicz Chief Operating Officer

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that Sharon Klugewicz has been appointed Chief Operating Officer. In this newly created position, Ms. Klugewicz will oversee all aspects of manufacturing, regulatory affairs, quality assurance and research & development. Ms. Klugewicz will report to Stavros Vizirgianakis, President and CEO of Misonix.

  • GlobeNewswire5 months ago

    Misonix to Present at the 8th Annual SVB Leerink Global Healthcare Conference on February 27

    Misonix, Inc. (MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, today announced that it will be participating in the 8th Annual SVB Leerink Global Healthcare Conference held at the Lotte New York Palace Hotel in New York City on Wednesday, February 27, 2019. Misonix President and Chief Executive Officer, Stavros Vizirgianakis will be conducting a fire-side chat in the Louis Room at 2:30 p.m. ET that day. The Misonix investor presentation is available in the “Investor Relations” section of the Company’s website at www.misonix.com.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of MSON earnings conference call or presentation 6-Feb-19 9:30pm GMT

    Q2 2019 Misonix Inc Earnings Call

  • What Kind Of Shareholder Appears On The Misonix, Inc.’s (NASDAQ:MSON) Shareholder Register?
    Simply Wall St.5 months ago

    What Kind Of Shareholder Appears On The Misonix, Inc.’s (NASDAQ:MSON) Shareholder Register?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...

  • Associated Press5 months ago

    Misonix: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Farmingdale, New York-based company said it had a loss of 9 cents. The maker of minimally invasive ultrasonic surgical devices for spine surgery posted revenue of $10.2 million ...

  • GlobeNewswire5 months ago

    Misonix Fiscal 2019 Second Quarter Revenue Rises 22% to a Record $10.2 Million

    FARMINGDALE, N.Y., Feb. 06, 2019 -- Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire6 months ago

    Misonix to Report Fiscal 2019 Second Quarter Financial Results and Host Conference Call and Webcast on February 6

    FARMINGDALE, N.Y., Jan. 22, 2019 -- Misonix, Inc. (NASDAQ: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that.

  • GlobeNewswire8 months ago

    Analysis: Positioning to Benefit within Vertex Pharmaceuticals, MISONIX, Whiting Petroleum, Kewaunee Scientific, Arotech, and Apollo Commercial Real Estate Finance — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 14, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of MSON earnings conference call or presentation 8-Nov-18 9:30pm GMT

    Q1 2019 Misonix Inc Earnings Call

  • Associated Press8 months ago

    Misonix: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Farmingdale, New York-based company said it had a loss of 29 cents. The maker of minimally invasive ultrasonic surgical devices for spine surgery posted revenue of $9.4 million ...